Euler Manenti (@emanenti) profile picture

MD PhD FACC INSTITUTO DE MEDICINA CARDIOVASCULAR CORA CENTER CLINICAL TRAILIST #diabetocardiology #CardioOncology#thrombocardiology

Porto Alegre, Brasil
Joined April 2009
Photo by Euler Manenti (@emanenti)Photo by Euler Manenti (@emanenti)Photo by Euler Manenti (@emanenti)Photo by Euler Manenti (@emanenti)Photo by Euler Manenti (@emanenti)Photo by Euler Manenti (@emanenti)Photo by Euler Manenti (@emanenti)Photo by Euler Manenti (@emanenti)Photo by Euler Manenti (@emanenti)Photo by Euler Manenti (@emanenti)
Euler Manenti retweeted
Discovery of a liver-heart axis. Prior liver injury-> heart attack risk How the immune system transmits inter-organ impact cell.com/cell-metabolism/ful…
19
85
4
327
25,856
Euler Manenti retweeted
A free, useful calculator from @dr_aac and his team at @MayoClinic that predicts the timing of weight regain after stopping semaglutide or tirzepatide, presented today at #ObesityWeek #OW2026 GLP-1 Weight-Regain Risk Calculator: glp1regainrisk.com
9
33
4
96
5,214
Are we judging AI solely by diagnostic accuracy, when its greatest potential may lie in reconstructing disease trajectories and revealing what fragmented healthcare has overlooked?
We'll be seeing a lot more of this. @katiebindley's diagnosis experience gift link wsj.com/health/wellness/how-…
1
100
Why did the Lp(a)HORIZON trial fail? pubmed.ncbi.nlm.nih.gov/4300… Wrong target? Wrong study design? Wrong population? Wrong drug? Wrong mechanism studied for Lp(a)? Some thoughts:
11
16
1
65
5,735
Euler Manenti retweeted
👉 MUST READ; A landmark EAS Statement in the post-Lp(a)HORIZON era in @ATHjournal ☝️The European Atherosclerosis Society @society_eas delivers a timely, evidence-based message following the neutral results of Lp(a)HORIZON. 1️⃣ 78% Lp(a) reduction ≠ cardiovascular benefit. We must distinguish a causal risk factor from a validated therapeutic target. 2️⃣ Lp(a) remains a major cardiovascular risk factor. Measure it at least once in every adult. Family screening remains essential. 3️⃣ LDL-C lowering is our strongest actionable strategy. Intensive control of LDL-C and other risk factors can mitigate Lp(a)-associated risk. 4️⃣ Timing may be everything. Can a few years of treatment reverse decades of cumulative atherogenic exposure? 5️⃣ The science is far from over. Ongoing RCTs with different Lp(a)-lowering agents are essential. ☝️My key takeaway: A negative trial should change our assumptions, not replace scientific evidence with speculation. ☝️ Measure Lp(a). Lower LDL-C. Control global risk. Keep testing hypotheses with RCTs. 🔗 atherosclerosis-journal.com/… @BNordestgaard @ProfKausikRay @MeralKayikcoglu @KronenbergLab @j_rvl @SamiaMoraMD
10
34
8
114
10,009
Euler Manenti retweeted
ATTAIN-OSA: oral GLP1 orforglipron improved sleep apnea severity (~18 vs ~5 hypoxic events/h) c/w placebo in obese pts w sleep apnea (whether or not they were using Cpap) Cost: Foundayo $149/mo Weight ⬇️10-11%, SBP ⬇️~7 mm Hg, effect likely weight-driven #ScientificSessions26
Replying to @AHAScience
ATTAIN-OSA results presented at #ScientificSessions26 Among adults with moderate-to-severe OSA and overweight or obesity without diabetes, orforglipron significantly reduced apnea-hypopnea index compared with placebo at 52 weeks, both in participants using and not using positive airway pressure therapy.
6
1
9
955
Euler Manenti retweeted
🤝@GoHealio caught up with @DLBHATTMD of @MountSinaiHeart at @ScientificSessions26 to discuss the late-breaking science from @American_Heart's meeting. Stay tuned for his expert perspective on HORIZON-Lp(a) and more!❤️
3
30
1,742
Euler Manenti retweeted
PROGRESS trial (NEJM): TAVR vs clinical surveillance in moderate aortic stenosis with at-risk features. RCT, 744 patients. Death or heart-failure event at 2 years: 16.7% vs 23.9%, risk difference −7.2 pp (95% CI −13.1 to −1.3), P = 0.02. currentcardio.com/studies/ta…
1
2
101
Euler Manenti retweeted
Replying to @NickCurzen
1/8: I am pleased to share with you the top-line results from the #PARAMOUNT trial of #coronary #plaque-based care that were presented this morning at #AHA26! The trial was supported by @Cleerlyhealth, to which I am a consultant. Here are the essentials:
2
1
1
456
Euler Manenti retweeted
facebook.com/share/v/1AAbzqg… 🫀 9 ECG patterns to know: Osborn → hypothermia Epsilon → ARVC De Winter → LAD occlusion Alternans → tamponade Wellens → LAD stenosis Coved ST → Brugada Delta → WPW Sawtooth → flutter Prominent U → hypokalemia 🔁 Save & share #ECG #EKG #Cardiology
3
159
1
564
19,289
Euler Manenti retweeted
Bom ver o Lula fazer vídeo desmentindo a Globo igual os Nordestinhos fizeram desmentindo o Nikolas. A esquerda aprendeu como se combate a extrema direita nas redes.
366
6,578
74
25,622
206,172
Euler Manenti retweeted
Only 4 days to the webinar Time is almost up: register today!
4
5
100
"long-awaited consensus" ."The long-awaited moment for heart failure prevention"
🫀Pharmacological treatment strategies to prevent #heartfailure across the cardiovascular-kidney-metabolic spectrum, an EJHF expert consensus statement: 📍Identify individuals at risk of developing HF: - Type 2 diabetes - Chronic kidney disease ± albuminuria - Hypertension and obesity - Atherosclerotic cardiovascular disease - Metabolic dysfunction-associated steatotic liver disease 📍Four foundational pharmacological strategies: 💊RAS inhibitors (ACEi/ARBs) 💊SGLT2 inhibitors 💊Non-steroidal MRAs (finerenone) 💊Incretin-based therapies (GLP-1 RAs and dual GLP-1/GIP agonists) 📍Early, accelerated treatment implementation: - Initiate complementary therapies early rather than delaying until clinical deterioration - Titrate rapidly and avoid unnecessary discontinuation - Individualize treatment according to clinical phenotype, risk, and tolerability 📍Structured monitoring and multidisciplinary care: - Laboratory monitoring at 1-4 weeks - Reintroduce therapies following temporary interruption when appropriate - Support nurse/pharmacist-led titration, digital monitoring, and patient education 📍Overcome implementation barriers: - Clinical inertia and polypharmacy - Renal safety concerns - Treatment costs and inequities - Fragmented healthcare delivery Read more in #EJHF @EJHFEiC : doi.org/10.1093/ejhf/xuag301 @escardio #HFA_ESC #HF #CKM
2
68
Relevant Topic in the Cardiologist's Daily Practice.
Great talk by @DrMarthaGulati on Brain impact after Cardiovascular Care & the relationship. @American_Heart #AHA2026 #CardioX
4
136
These findings may help inform clinical selection of add-on non-statin therapy in patients with ASCVD who do not reach lipid goals after statin therapy.
No trial will randomize evolocumab against ezetimibe, so this is the evidence we get. 544,103 ASCVD patients with prior statin use, target trial emulation, MI at 4 years, three messages: 1️⃣ HR 0.80 (95% CI 0.70 to 0.91) 2️⃣ 5.9% vs 7.8% 3️⃣ NNT about 50 sciencedirect.com/science/ar…
1
2
175
Euler Manenti retweeted
📌My go-to Slide for a Quick Recap of all the Current #AHA and #ESC Recommendations for #DAPT Thanks to @MyJSCAI and authors of ➡️doi.org/10.1016/j.jscai.2023…………
34
2
82
10,050
Euler Manenti retweeted
La edición de noviembre de 2026 de Psychiatric Times dedica su portada a revisar las promesas y limitaciones de los agonistas del receptor GLP-1 en psiquiatría. Uno de los campos con evidencia más sólida es el manejo del aumento de peso asociado a antipsicóticos. El ensayo COaST, publicado en The Lancet Psychiatry en 2025, encontró que la semaglutida produjo una reducción de peso del 13.46% respecto al placebo en pacientes con esquizofrenia y obesidad inducida por clozapina, además de mejorar parámetros metabólicos. Pero hay otras aplicaciones en investigación. Adicciones: un ensayo clínico de fase 2 encontró que la semaglutida redujo el deseo de consumir alcohol y la cantidad ingerida por día de consumo. También existen señales preliminares sobre nicotina, aunque todavía no hay evidencia suficiente para establecer recomendaciones terapéuticas definitivas. Trastornos de la conducta alimentaria: algunos estudios sugieren una reducción de los episodios de atracones y del deseo intenso de comer. Sin embargo, también existen preocupaciones por la restricción alimentaria patológica, especialmente en personas vulnerables a desarrollar anorexia nerviosa. Neurodegeneración: aunque estudios observacionales habían sugerido una menor incidencia de demencia, los ensayos EVOKE y EVOKE Plus no encontraron que la semaglutida retrasara la progresión del Alzheimer en etapas tempranas. Seguridad psiquiátrica: los metaanálisis de ensayos clínicos no encontraron un incremento significativo de conducta suicida o autolesiones frente al placebo. En enero de 2026, la FDA solicitó retirar la advertencia sobre ideación y conducta suicida del etiquetado de estos medicamentos. La revisión también planteó: ¿qué ocurre cuando la supresión farmacológica del apetito comienza a normalizarse como una expectativa social y no exclusivamente como una intervención médica? cdn.sanity.io/files/0vv8moc6…
5
53
4
200
10,423
Approximately 50 million people are living with dementia worldwide, a number projected to reach more than 150 million by 2050. Dementia has emerged as one of the most pressing public health challenges globally. In this lecture, Prof. Ruth Frikke-Schmidt takes us through human evidence on well-established and emerging cardiovascular risk factors and risk of dementia and discuss important genetic risk factors and how they can be used in future risk prediction strategies: eas.to/OpenNov26
3
1
7
457
Finerenone vs spironolactone in heart failure with mildly reduced or preserved ejection fraction: a real-world study Finerenone initiation was associated with lower 12-month clinical event and hyperkalaemia risks than spironolactone initiation @mvaduganathan @gcfmd @SJGreene_md academic.oup.com/eschf/artic…
1
35
99
4,186